Kevin M. Kalinsky, MD, Columbia University Medical Center
Articles
Future Directions for Treatment of TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Sequencing Therapies for mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for BRCA+ mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Testing for PD-L1 Expression in mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for Metastatic TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Current Trials for Treatment of Early Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Emerging Data on Biomarkers in ES TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
ICI-Based Therapy in TNBC: Immune-Related Adverse Events
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Early Stage TNBC: Phase 3 IMpassion031 Study
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Key Trials in ICI-Based Therapy for Early Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Role of pCR in Early Stage TNBC Management
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for Early-Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
